DUBLIN--(BUSINESS WIRE)--The "Natural Killer Cell Therapies - Competitive Landscape, Technology and Pipeline Analysis, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
" Natural Killer Cell Therapies - Competitive Landscape, Technology and Pipeline Analysis, 2018" provides comprehensive Insight about pipeline drugs along with technologies involved across this Cell Therapy. The report provides the detailed analysis of 30+ products along with 20+ companies involved. The report also covers a separate section for the Natural Killer Augmenters including Natural Killer Cell Activators and Natural Killer Enhancers. European Commission has granted Orphan Drug Designation to IPH4102 for the treatment of Cutaneous T-Cell Lymphoma.
Products covered by Phase
- Phase II and Phase I
- Pre-clinical
Overview of pipeline development activities for Natural Killer Cell Therapies
Pipeline analysis of 30+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
Therapeutic segmentation of products for Natural Killer Cell Therapies
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Cell Therapy.
Companies Mentioned
- Affimed
- Altor Bioscience Corporation
- AvidBiotic Corporation
- Bristol-Myers Squibb
- Celgene
- CureTech
- CytoVac
- Dynavax
- Fate Therapeutics
- Five Prime Therapeutics
- Fortress Biotech
- GamidaCell
- Glycostem Therapeutics
- Green Cross Corporation
- iCell Gene Therapeutics
- Innate Pharma
- Multimmune GmbH
- NantKwest
- Nohla Therapeutics
- PersonGen BioTherapeutics (Suzhou)
- Sorrento Therapeutics
- Surface Oncology
- ZIOPHARM Oncology
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/kn5mj3/natural_killer?w=4
